The company
Vertex Pharmaceuticals Incorporated
VRTX · Nasdaq
VRTX stood above a rising 150-day average in 30 of the last 52 weekly readings, including each of the last 18 weeks. It is 4.5% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- In trend
- Weeks in an uptrend
- 18 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $245.6M
- Officials’ trades on record
- 65
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 30 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
65 disclosed lines: House 36, Senate 7, executive 22; 22 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| David J. Taylor House: U.S. House ClerkOH02 | sold | $1k–$15k | 26 Aug 2026filed 5 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 23 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 12 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 3 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 22 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 28 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Duncan McKechnieEVP, Chief Commercial Officer | sold | 1,541at $519.00 | 2 Jul 2026filed 7 Jul 2026 |
| Ourania TatsisEVP, Chief Reg. & Quality Off. | sold | 1,500at $524.99 | 2 Jul 2026filed 7 Jul 2026 |
| Joy LiuEVP and Chief Legal Officer | sold | 828at $502.71 | 1 Jul 2026filed 6 Jul 2026 |
| Carmen BozicEVP and CMO | sold | 596at $482.50 | 26 Jun 2026filed 30 Jun 2026 |
| Carmen BozicEVP and CMO | sold | 1,020at $462.17 | 18 Jun 2026filed 23 Jun 2026 |
| Carmen BozicEVP and CMO | sold | 4,062at $450.00 | 15 Jun 2026filed 17 Jun 2026 |
| Carmen BozicEVP and CMO | sold | 1,745at $450.00 | 5 Jun 2026filed 9 Jun 2026 |
| Joy LiuEVP and Chief Legal Officer | sold | 828at $439.91 | 1 Jun 2026filed 3 Jun 2026 |
| Carmen BozicEVP and CMO | sold | 1,974at $450.00 | 29 May 2026filed 2 Jun 2026 |
| Carmen BozicEVP and CMO | sold | 1,354at $453.45 | 15 May 2026filed 19 May 2026 |
| Mark E. BunnageEVP, Chief Scientific Officer | sold | 33at $453.45 | 15 May 2026filed 19 May 2026 |
| Carmen BozicEVP and CMO | sold | 6,988at $450.00 | 12 May 2026filed 14 May 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.